Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ganirelix Acetate

FDA-approved product (injectable, injection), marketed as Fyremadel, Ganirelix Acetate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ganirelix Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Female infertility
  • Positive regulation of ovulation
  • Reproductive Techniques, Assisted

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Anti-gonadotropin-releasing hormones
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA69.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ganirelix Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ganirelix Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Initiation of Ovarian Stimulation With Recombinant-human FSH (Bemfola®) in the Late Follicular Phase

    NCT03767218 · start 2018-11-01

    Registered record
    Registry ID
    NCT03767218
    Conditions
    Infertility, Female
    Interventions
    Late follicular phase stimulation with recombinant-human FSH; Early follicular phase stimulation with recombinant-human FSH
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-11-01
    Completion
    2022-11-25
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility, Female
    InterventionLate follicular phase stimulation with recombinant-human FSH; Early follicular phase stimulation with recombinant-human FSH
    PhasePhase 3
    Registry statusCompleted

  • Corifollitropin Alpha and Ovarian Response

    NCT04416607 · start 2018-06-15

    Registered record
    Registry ID
    NCT04416607
    Conditions
    Infertility, Female
    Interventions
    Corifollitropin Alfa; Menotropins
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-06-15
    Completion
    2019-01-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility, Female
    InterventionCorifollitropin Alfa; Menotropins
    PhaseNot applicable
    Registry statusCompleted

  • Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome

    NCT04327934 · start 2017-12-01

    Registered record
    Registry ID
    NCT04327934
    Conditions
    Polycystic Ovary Syndrome; Hypertension
    Interventions
    GnRH antagonist; GnRH antagonist + MethylTESTOSTERone 5 MG
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2017-12-01
    Completion
    2022-06-30
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Ovary Syndrome; Hypertension
    InterventionGnRH antagonist; GnRH antagonist + MethylTESTOSTERone 5 MG
    PhaseEarly phase 1
    Registry statusTerminated

  • Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient

    NCT03300518 · start 2017-11-15

    Registered record
    Registry ID
    NCT03300518
    Conditions
    Infertility
    Interventions
    Follitropin Beta; MSD; Ganirelix; hCG; estradiol valerate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-11-15
    Completion
    2021-08-18
    Enrolment
    552

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    InterventionFollitropin Beta; MSD; Ganirelix; hCG +1 more
    PhaseNot applicable
    Registry statusCompleted

  • Cetrorelix and Ganirelix Flexible Protocol for (IVF)

    NCT03477929 · start 2017-11-15

    Registered record
    Registry ID
    NCT03477929
    Conditions
    Infertility/Sterility
    Interventions
    Ganirelix Acetate; Cetrorelix Acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-11-15
    Completion
    2019-01-15
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility/Sterility
    InterventionGanirelix Acetate; Cetrorelix Acetate
    PhasePhase 4
    Registry statusUnknown

  • Hormonal Mechanisms of Sleep Restriction - Axis Study

    NCT03142893 · start 2017-05-08

    Registered record
    Registry ID
    NCT03142893
    Conditions
    Sleep Restriction
    Interventions
    Ketoconazole Pill; Ganirelix; Dexamethasone; Dexamethasone Injection; Cosyntropin Injectable Product; Recombinant Human Luteinizing Hormone; Hydrocortisone Injection; Gonadorelin; Corticorelin; Placebo oral capsule; Saline Solution; Saline Solution for Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2017-05-08
    Completion
    2026-06-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Restriction
    InterventionKetoconazole Pill; Ganirelix; Dexamethasone; Dexamethasone Injection +8 more
    PhasePhase 1
    Registry statusActive not recruiting

  • To Compare and Evaluate the Efficacy and Safety of Ganilever PFS(Prefilled Syringe) and Orgalutran®

    NCT03051087 · start 2016-10

    Registered record
    Registry ID
    NCT03051087
    Conditions
    Controlled Ovarian Stimulation
    Interventions
    Ganirelix acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-10
    Completion
    2018-03
    Enrolment
    255

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionControlled Ovarian Stimulation
    InterventionGanirelix acetate
    PhasePhase 4
    Registry statusCompleted

  • Menopause Effects on Vascular Function

    NCT03236545 · start 2016-07-01

    Registered record
    Registry ID
    NCT03236545
    Conditions
    Cardiovascular Risk Factor
    Interventions
    No to Low Endogenous Estrogen; Estradiol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-07-01
    Completion
    2022-11-01
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Risk Factor
    InterventionNo to Low Endogenous Estrogen; Estradiol
    PhaseNot applicable
    Registry statusCompleted

  • Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors

    NCT02796105 · start 2016-06

    Registered record
    Registry ID
    NCT02796105
    Conditions
    Infertility
    Interventions
    Progevera; Orgalutran
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-06
    Completion
    2017-07-10
    Enrolment
    232

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    InterventionProgevera; Orgalutran
    PhasePhase 4
    Registry statusCompleted

  • Effectiveness and Safety Study of Fixed Versus Flexible of Gonadotropin-releasing Hormone Antagonist Protocol

    NCT02635607 · start 2016-01

    Registered record
    Registry ID
    NCT02635607
    Conditions
    Infertility
    Interventions
    Follitropin Beta; Ganirelix; Ganirelix; rhCG; triptorelin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2016-01
    Completion
    2017-03
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    InterventionFollitropin Beta; Ganirelix; Ganirelix; rhCG +1 more
    PhaseNot applicable
    Registry statusUnknown

  • Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response.

    NCT02118051 · start 2013-09

    Registered record
    Registry ID
    NCT02118051
    Conditions
    Infertility
    Interventions
    Ganirelix 0.25 mg.; Recombinant choriogonadotropin alfa; Micronized natural progesterone.
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-09
    Completion
    2017-06
    Enrolment
    234

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    InterventionGanirelix 0.25 mg.; Recombinant choriogonadotropin alfa; Micronized natural progesterone.
    PhasePhase 3
    Registry statusCompleted

  • Endometrial Injury and IVF Outcome Parameters in Patients With Failed IVF Cycles

    NCT01798862 · start 2013-03

    Registered record
    Registry ID
    NCT01798862
    Conditions
    Repeated Implantation Failures
    Interventions
    Endometrial injury by hysteroscopy or pipelle sampling; Proceed to COH directly
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2013-03
    Completion
    2016-06
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRepeated Implantation Failures
    InterventionEndometrial injury by hysteroscopy or pipelle sampling; Proceed to COH directly
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation

    NCT01645241 · start 2012-07

    Registered record
    Registry ID
    NCT01645241
    Conditions
    INFERTILITY; Fertility Preservation; Ovulation Induction; Vitrification; Oocyte Donation
    Interventions
    gonadotropins plus GnRH antagonists; ganirelix
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-07
    Completion
    2013-12
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionINFERTILITY; Fertility Preservation; Ovulation Induction; Vitrification +1 more
    Interventiongonadotropins plus GnRH antagonists; ganirelix
    PhaseNot applicable
    Registry statusCompleted

  • Addition of Prednisolone and Heparin in Patients Undergoing IVF With Failed IVF Cycles

    NCT01590173 · start 2012-01

    Registered record
    Registry ID
    NCT01590173
    Conditions
    Infertility
    Interventions
    Prednisolone and Heparin during COH for IVF; COH for IVF
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2012-01
    Completion
    2016-07
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    InterventionPrednisolone and Heparin during COH for IVF; COH for IVF
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Effect of Oocyte Vitrification on Fertilization Rate, Embryo Quality and Development

    NCT01422395 · start 2011-08

    Registered record
    Registry ID
    NCT01422395
    Conditions
    Fertility
    Interventions
    Freezing
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2011-08
    Completion
    2013-05
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFertility
    InterventionFreezing
    PhaseEarly phase 1
    Registry statusCompleted